Clinical trials: Depressive
Treatment Resistant Depression
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
- Trial name
- NCT05144789
- Testing
- Active TBS-DLPFC, Active TBS-DMPFC
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Stanford University
Treatment Resistant Depression
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
- Trial name
- NCT03680781
- Testing
- Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Major Depressive Disorder
Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression
Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being.
- Trial name
- NCT05224063
- Testing
- Neuronavigated rTMS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder.
- Trial name
- RELIANCE-II (NCT04855747)
- Testing
- REL-1017
- Where
- 70 sites in United States
- Volunteers
- 236 people
- Sponsor
- Levomecor Inc.
Major Depressive Disorder, Depression
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
- Trial name
- RELIGHT (NCT06011577)
- Testing
- REL-1017
- Where
- 36 sites in United States
- Volunteers
- 27 people
- Sponsor
- Levomecor Inc.
Treatment Resistant Major Depressive Disorder
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy…
- Trial name
- ASCERTAINTRD (NCT02977299)
- Testing
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Where
- 13 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Deep Brain Stimulation for Treatment Resistant Depression
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant…
- Trial name
- NCT00367003
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Major Depressive Disorder, Social Anxiety Disorder
Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response
Many patients with Major Depressive Disorder (MDD) and generalized Social Anxiety Disorder (gSAD) are treated with cognitive behavioral therapy (CBT) but few have meaningful improvement.
- Trial name
- NCT03175068
- Testing
- CBT, ST
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Posttraumatic Stress Disorder, Major Depressive Disorder
Predicting SSRI Efficacy in Veterans With PTSD
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective…
- Trial name
- SSRI (NCT04183205)
- Testing
- LDAEP, sertraline
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Major
Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression
In this project, the investigators use real-time fMRI neurofeedback (rtfMRI-nf) to causally relate dysfunction of right anterior insula (rAI) and right superior temporal sulcus (rSTS) connectivity with the intensity of repetitive…
- Trial name
- CNF-RNT (NCT06219681)
- Testing
- Active neurofeedback
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Depressive Disorder
Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform
Malawi is a low-income country in sub-Saharan Africa that has limited resources to address a significant burden of disease-including HIV/AIDS.
- Trial name
- IC3D (NCT04777006)
- Testing
- Problem Management Plus, Antidepressant Therapy
- Where
- Malawi
- Volunteers
- 487 people
- Sponsor
- RAND
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Symptoms, Depression
Feasibility & Acceptability of a Virtual Sister Circle Intervention for Black Women With Depressive Symptoms
The purpose of this study is to evaluate the feasibility and acceptability of a protocol for middle- and older-aged Black women with depressive symptoms.
- Trial name
- NCT04837573
- Testing
- Sister Circle protocol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kia Skrine Jeffers, PhD, RN, PHN
Major Depressive Disorder
HypErthermia as an Additional Treatment for the Biology and Experience of Depression
This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or…
- Trial name
- HEATBED (NCT05041361)
- Testing
- Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Depression
HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18…
- Trial name
- HEATBED2 (NCT05708976)
- Testing
- Cognitive Behavioral Therapy (CBT), Active Whole-Body Hyperthermia (Active WBH)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder
Opiate Suicide Study in Patients With Major Depression
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately…
- Trial name
- AFSP (NCT04116528)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Depressive Symptoms
A Systems-Level Intervention for Rural Adults With Depression
This study aims to test the effectiveness of a computer-assisted cognitive behavioral therapy for depression among rural adults.
- Trial name
- NCT04502186
- Testing
- Raising Our Spirits Together, Enhanced Control Condition
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of Michigan
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles